NCT01559077View on ClinicalTrials.gov

Trial to Evaluate Safety, Tolerability, and Parmacokinetics of ALN-TTR02 in Healthy Volunteer Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

June 30, 2012

Study Completion Date

November 30, 2012

Conditions
TTR-mediated Amyloidosis
Interventions
DRUG

ALN-TTR02

Dose levels between 0.01 and 0.5 mg/kg by intravenous (IV) infusion

DRUG

Sterile Normal Saline (0.9% NaCl)

Calculated volume to match active comparator

Trial Locations (2)

LS2 9LH

Clinical Site, Leeds

NW10 7EW

Clinical Site, London

Sponsors
All Listed Sponsors
lead

Alnylam Pharmaceuticals

INDUSTRY